10 Most Undervalued US Stocks According to Hedge Funds

​6. Pfizer Inc. (NYSE:PFE)

Forward Price to Earnings Ratio: 8.56

Number of Hedge Fund Holders: 81

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc. (NYSE:PFE) announced receiving marketing authorization from the European Commission to expand the use of HYMPAVZI (marstacimab) for hemophilia A and B patients aged 12+ who have developed inhibitors.

​Management noted that roughly 20% of hemophilia A patients and 3% of hemophilia B patients develop these inhibitors, which severely limit their treatment options. Moreover, recurring bleeding can cause joint damage and significantly disrupt daily life. In this situation, HYMPAVZI, which is a once-weekly subcutaneous treatment, provides a meaningful convenience advantage over existing treatments.

​During the Phase 3 clinical trials, Pfizer Inc. (NYSE:PFE) noted that HYMPAVZI reduced treated bleeding rates by 93% compared to on-demand therapy. Moreover, long-term follow-up data of up to 53 months also showed sustained results. In addition to the European Commission, the FDA is reviewing an expanded application covering younger patients aged 6+. The decision is expected in Q2 2026. HYMPAVZI is already FDA-approved for patients 12+ without inhibitors.

​Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company focused on the discovery, development, manufacturing, marketing, sale, and distribution of biopharmaceutical products worldwide.

Click to continue reading and see the 5 Most Undervalued US Stocks According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.